¸Þµð¾÷

´ëÇк´¿ø Çѹ溴¿ø
Á¾ÇÕº´¿ø ³ëÀκ´¿ø
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹Á¤º¸
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ëºÐ¾ç¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
¸ÞµðÅå
´ëÇк´¿ø Á¾ÇÕº´¿ø Çѹ溴¿ø Ä¡°úº´¿ø ÇÑÀÇ¿ø ³ëÀÎÀü¹®º´¿ø º¸°Ç¼Ò
¼­¿ï ºÎ»ê ÀÎõ ´ë±¸ ´ëÀü ±¤ÁÖ ¿ï»ê °æ±â °­¿ø ÃæºÏ Ãæ³² °æºÏ °æ³² ÀüºÏ Àü³² Á¦ÁÖ ¼¼Á¾
Ä¡°ú ¾È°ú ÇǺΰú ¼ºÇü¿Ü°ú »êºÎÀΰú ºñ´¢±â°ú ¿Ü°ú ³»°ú Á¤Çü¿Ü°ú À̺ñÀÎÈÄ°ú ¼Ò¾Æ°ú ¾à±¹

¸ñ·Ï ¼öÁ¤ »èÁ¦

¼¼ºê¶õ½ºº´¿ø ´ëÇѹé¹ÝÁõÇÐȸ Á¦ 10Â÷ ½ÉÆ÷Áö¾ö : 2019-04-06

ÃßõÇϱâ
¿¬¼ö°­Á À̹øÁÖ BEST
 
¼¼ºê¶õ½ºº´¿ø ´ëÇѹé¹ÝÁõÇÐȸ Á¦ 10Â÷ ½ÉÆ÷Áö¾ö : 2019-04-06
±³À°ÀÏÀÚ : 2019-04-06
±³À°Àå¼Ò : ¼¼ºê¶õ½ºº´¿ø Á¾ÇÕ°ü 3Ãþ 337È£  
±³À°ÁÖÁ¦ : ´ëÇѹé¹ÝÁõÇÐȸ Á¦ 10Â÷ ½ÉÆ÷Áö¾ö
ÁÖÃÖ±â°ü : ´ëÇÑÇǺΰúÇÐȸ
½ÃÇà±â°ü(ÁöºÎ/°ú) : ´ëÇѹé¹ÝÁõÇÐȸ  
´ã´çÀÚ : ¿À»óÈ£
¿¬¶ôó : 02-2228-2080  
À̸ÞÀÏ : kda@derma.or.kr      
±³À°Á¾·ù : ÇǺΰú      
Âü¼®¿¹»óÀοø : 100¸í
Èñ¸ÁÆòÁ¡ : 4Á¡  
Áö¿ª : ¼­¿ïƯº°½Ã
±³À°½Ã°£ : 4 ½Ã°£ 20ºÐ  
¼¼ºÎ¼ö°­·á : 20,000¿ø      
ºñ°í ÇöÀåµî·Ï¸¸ °¡´É: ÇǺΰúÀü¹®ÀÇ 2¸¸¿ø, ÇǺΰúÀü°øÀÇ 1¸¸¿ø      

±¸ºÐ ¿ùÀÏ °­ÀǽǠ½Ã°£ ±³À°Á¦¸ñ  °­»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 04-06 337È£ 13:10~13:30 Interplay between oxidative stress and immune system  ¿À»óÈ£(¿¬¼¼ÀÇ´ë) 
±³À°½Ã°£ 04-06 337È£ 13:30~13:50 A symphony of various kinds of immune cells responsible for vitiligo  ÀÌ»óÈÆ(¼øõÇâÀÇ´ë) 
±³À°½Ã°£ 04-06 337È£ 13:50~14:10 Melanocyte stem cells and paracrine factors for melanocyte regeneration in vitiligo  °­Èñ¿µ(¾ÆÁÖÀÇ´ë) 
±³À°½Ã°£ 04-06 337È£ 14:10~14:30 Pratical tips for the treatment of segmental vitiligo  À̵¿À±(¼º±Õ°üÀÇ´ë) 
±³À°½Ã°£ 04-06 337È£ 14:30~14:50 Protocols of phototherapy in vitiligo treatment  ½ÅÁ¤Çö(ÀÎÇÏÀÇ´ë) 
±³À°½Ã°£ 04-06 337È£ 14:50~15:10 The bottomline of surgical treatments of vitiligo  ¹ÚÁöÈÆ(¿ìÅÂÇÏÇѽ°æÇǺΰú) 
È޽Ġ04-06 337È£ 15:10~15:40 coffee break  () 
±³À°½Ã°£ 04-06 337È£ 15:40~16:10 FoxP3 regulatory T cells in immune-mediated tissue injury  ÃÖÀ±¼®(Ãæ³²ÀÇ´ë Ç÷¾×³»°ú) 
±³À°½Ã°£ 04-06 337È£ 16:10~16:30 Introduction of recent clinical trials and upcoming targeted medical therapy  ¹èÁ¤¹Î(°¡Å縯ÀÇ´ë) 
±³À°½Ã°£ 04-06 337È£ 16:30~16:50 Immune checkpoint blockers and vitiligo  ÃÖÁ¾¿ø(Ãæ³²ÀÇ´ë) 
±³À°½Ã°£ 04-06 337È£ 16:50~17:10 Comorbidities of vitiligo and laboratory tests for evaluation of comorbidities  ÀÌÈñÁ¤(Â÷ÀÇ°ú´ë) 
±³À°½Ã°£ 04-06 337È£ 17:10~18:00 Development of vitiligo after immunotherapy for breast cancer  ±èÁ¦¹Î(¿¬¼¼ÀÇ´ë) 
ÆÄ¿ö¸µÅ© ±¤°íµî·Ï
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
¸Þµð¾÷
" ¼¼ºê¶õ½ºº´¿ø ´ëÇѹé¹ÝÁõÇÐȸ Á¦ 10Â÷ ½ÉÆ÷Áö¾ö : 2019-04-06""ÀÇ ÀÌ¿ëÈı⳪ Ãßõ´ñ±ÛÀ» ³²°Ü À¯¿ëÇÑ Á¤º¸·Î °øÀ¯ÇսôÙ. ^^
¡å
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
 
¸ñ·Ï ¼öÁ¤ »èÁ¦
ÀÌÀü±Û ´ëÇÑ»êºÎÀΰúÀÇ»çȸ Á¦41Â÷ Ãá°èÇмú´ëȸ : 2019-04-07
´ÙÀ½±Û ±¤ÁÖÀü³²°³¿ø³»°úÀÇ»çȸ Ãá°èÇмú´ëȸ : 2019-04-06
¹øÈ£ Á¦¸ñ Ãßõ Á¶È¸ µî·ÏÀÏ
315 ´ëÀü ´ëÇѳëÀÎÁ¤½ÅÀÇÇÐȸ Á¦10ȸ Ä¡¸ÅÁø·áÀÇ»ç Àü¹®È­±³À° (part3, 1ÀÏÂ÷) : 2018-08-25 0 762 2018-08-08
314 ¼­¿ï ¼¼ºê¶õ½ºº´¿ø 2018 Yunsei Nuclear Medicien Review course : 2018-08-25 0 532 2018-08-08
313 ¼­¿ï °­µ¿°æÈñ´ëÇб³º´¿ø 2018 °­µ¿°æÈñ´ëÇб³ Á¤Çü¿Ü°ú ½ÉÆ÷Áö¿ò : 2018-08-25 0 1,759 2018-08-08
312 ±¤ÁÖ Àü³²´ëÇб³º´¿ø 2018³â Á¦4ȸ ½Å°æ¿Ü°ú °³¿øÀÇ ¿¬¼ö°­Á : 2018-08-25 0 718 2018-08-08
311 ¼­¿ï 2018³âµµ ´ëÇѺ´¸®ÇÐȸ °øÅ뿪·®±³À° : 2018-08-25 0 607 2018-08-08
310 ÀÎõ ´ëÇѼҾƽÉÀåÇÐȸ Á¦ 21ȸ Update symposium of pediatric cardiology and cardiac surgery : 2018-08-25 0 477 2018-08-08
309 ¼­¿ï °Ç±¹´ëÇб³ÃæÁÖº´¿ø ´ç´¢º´, Àν¶¸°ÆßÇÁ ¿öÅ©¼¥ : 2018-08-25 0 1,031 2018-08-08
308 ±¤ÁÖ Á¶¼±´ëÇб³º´¿ø 2018 È£³²Ç×¹®Áúȯ ¿¬±¸È¸ : 2018-08-25 0 1,739 2018-08-08
307 ¼­¿ï ´ëÇѼҾƳ»ºÐºñÇÐȸ ºñ¸¸¿¬±¸Áý´ãȸ 2018³â 3Â÷ : 2018-08-23 0 368 2018-08-08
306 ºÎ»ê ºÎ»ê½Ã°³¿ø³»°úÀÇ»çȸ ¿¬¼ö°­Á : 2018-08-21 0 454 2018-08-08
305 Á¦ÁÖ Á¦ÁÖ³»ºÐºñÇÐȸ Á¦ 41Â÷ ¿¬¼ö°­Á : 2018-08-20 0 535 2018-08-08
304 ¼­¿ï ´ëÇѳ»°úÇÐȸ Á¦12Â÷ ÁöµµÀü¹®ÀÇ ±³À° : 2018-08-20 0 1,754 2018-08-08
303 ¼­¿ï Á¦42ȸ 2018³â ´ëÇÑÀϹݰúÀÇ»çȸ ÇÏ°è ¿¬¼ö°­Á : 2018-08-19 0 463 2018-08-08
302 ¼­¿ï ¼­¿ï´ëÇб³º´¿ø Á¦25Â÷ ¼­¿ï½ÉÆ÷Áö¿ò : 2018-08-19 0 548 2018-08-08
301 ¼­¿ï Á¦4ȸ ´ëÇѽŰæ¿Ü°úº´¿øÇùÀÇȸ Çмú´ëȸ : 2018-08-19 0 1,276 2018-08-08
1381 | 1382 | 1383 | 1384 | 1385 | 1386 | 1387 | 1388 | 1389 | 1390
 
Ä¿¹Â´ÏƼ
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ë¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
º´¿øȨÆäÀÌÁö
¸ÞµðÅå
ÇÑÀÇ¿ø
¼ºÇü¿Ü°ú
Ä¡°ú
¾È°ú
¿©¼ºº´¿ø
³»°ú
Á¤Çü¿Ü°ú
ÇǺΰú
¼Ò¾Æ°ú
À̺ñÀÎÈÄ°ú
ºñ´¢ÀÇÇаú
¿ä¾çº´¿ø
ÀçÈ°ÀÇÇаú
µ¿¹°º´¿ø
±âŸº´ÀÇ¿ø
Ãë¾÷°ü·Ã
Áö¿ø¼­¾ç½Ä
¼­·ù¾ç½Ä
¸Þµð¾÷ ¸ð¹ÙÀÏÀ¥
¸Þµð¾÷